Overview

Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Primary objective: - to assess the efficacy of SSR149744C for the prevention of ventricular arrhythmia-triggered ICD interventions. Secondary objectives: - to assess versus placebo the tolerability of the different dose regimens of SSR149744C in the selected population. - to document SSR149744C plasma level during the study.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi